Clinical trial results for anti-TIGIT antibodies have shown that the combination of anti-TIGIT with anti-PD-1/PD-L1 was associated with clinical activity in previously treated patients with ESCC. Here, CD274 is linked to esophageal squamous cell carcinoma.